Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Why is Jiangsu Hengrui Pharmaceuticals Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 3.76% and Operating profit at 4.45% over the last 5 years

The company declared negative results in Mar'25 after positive results in Dec'24

INTEREST(9M) At CNY 12.35 MM has Grown at 272.72%
OPERATING PROFIT(Q) Lowest at CNY 1,285 MM
OPERATING PROFIT MARGIN(Q) Lowest at 17.3 %

With ROE of 12.29%, it has a very expensive valuation with a 8.72 Price to Book Value

Over the past year, while the stock has generated a return of 16.75%, its profits have risen by 32.1% ; the PEG ratio of the company is 2.2
At the current price, the company has a high dividend yield of 0.3

Majority shareholders : Non Institution

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jiangsu Hengrui Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. for you?

Medium Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

11.68%

0.87

31.38%

China Shanghai Composite

15.17%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.76%

EBIT Growth (5y)

4.45%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.57

Tax Ratio

12.26%

Dividend Payout Ratio

18.49%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

99,562.58%

ROE (avg)

135,472.87%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

8.72

EV to EBIT

62.58

EV to EBITDA

55.89

EV to Capital Employed

20.86

EV to Sales

15.88

PEG Ratio

2.21

Dividend Yield

0.25%

ROCE (Latest)

33.33%

ROE (Latest)

12.29%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 11,987.25 MM

RAW MATERIAL COST(Y)

Fallen by -1.67% (YoY

CASH AND EQV(HY)

Highest at CNY 76,706.38 MM

DEBT-EQUITY RATIO (HY)

Lowest at -67.88 %

DEBTORS TURNOVER RATIO(HY)

Highest at 4.55 times

-7What is not working for the Company

INTEREST(9M)

At CNY 12.35 MM has Grown at 272.72%

OPERATING PROFIT(Q)

Lowest at CNY 1,285 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 17.3 %

PRE-TAX PROFIT(Q)

At CNY 1,388.57 MM has Fallen at -32.96%

Here's what is working for Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Operating Cash Flow

Highest at CNY 11,987.25 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Cash and Eqv

Highest at CNY 76,706.38 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -67.88 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 4.55 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -1.67% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Interest

At CNY 12.35 MM has Grown at 272.72%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Profit

Lowest at CNY 1,285 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 17.3 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

At CNY 1,388.57 MM has Fallen at -32.96%

over average net sales of the previous four periods of CNY 2,071.34 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)